Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 IN SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 IN SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and cellular metabolism. Dextrose 5% supplies calories and water for hydration. Sodium chloride 0.3% supplies sodium and chloride ions for extracellular fluid volume and electrolyte balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
10-40 mEq potassium chloride intravenously, rate not exceeding 10 mEq/hour or 200 mEq/24 hours, based on serum potassium levels.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal half-life approximately 1-2 hours for plasma potassium; clinical effect persistence depends on total body potassium deficit.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal excretion >90% as potassium ion; minimal biliary/fecal (<5%).
Category C
Category A/B
Electrolyte
Electrolyte